ALLO Allogene Therapeutics, Inc.
Listings ·
Stockholders approved raising authorized common stock from 400,000,000 to 800,000,000 at the June 18, 2026 meeting; 345,024,351 shares were outstanding on the April 20 record date. A sales supplement filed June 22 covers up to $135.0 million of stock sales through TD Securities (U.S.A.) LLC.
The sales agreement dates to 2019 and was amended in 2022 and 2023. TD Cowen can receive up to 3.0% of gross proceeds, and the prospectus lists 100,200,000 shares issued in April at $2.00 a share.
Allogene had $266.9 million in cash and investments at March 31, 2026, after an April offering with $200.4 million gross proceeds. Its first-quarter net loss was $42.6 million, and its key ALPHA3 comparison rests on 12 patients per arm.
Factor Bioscience sued Cellectis and AstraZeneca in Delaware federal court on Sept 26, 2025, over TALEN gene-editing technology. Allogene is not a party, but it licenses that technology from Cellectis and says Factor may still sue it directly.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell product candidates, meaning off-the-shelf CAR T therapies made from healthy donor cells, for cancer and autoimmune diseases. Its three core programs are cema-cel, ALLO-316 and ALLO-329. Cemacabtagene ansegedleucel (cema-cel, previously ALLO-501A) targets CD19 and is in the pivotal Phase 2 ALPHA3 trial as a first-line treatment for large B-cell lymphoma. ALLO-316 targets CD70 and is being developed for renal cell carcinoma in the TRAVERSE trial. ALLO-329 targets both CD19 and CD70 and is in development for systemic lupus erythematosus, idiopathic inflammatory myopathies and systemic sclerosis. The company uses Cellectis TALEN gene editing and Arbor Biotechnologies CRISPR technology to engineer T cells that lack functional T cell receptors, and its Dagger technology incorporates an anti-CD70 CAR. Its manufacturing facility in Newark, California, is called Cell Forge 1. The company states that multiple clinical readouts are expected in the second quarter of 2026.
| Product or program | What it is | Stage |
|---|---|---|
| cemacabtagene ansegedleucel (cema-cel, ALLO-501A) | Allogeneic CD19-targeted CAR T therapy for first-line large B-cell lymphoma | Pivotal Phase 2 (ALPHA3), enrolling |
| ALLO-316 | Allogeneic CD70-targeted CAR T therapy for renal cell carcinoma | |
| ALLO-329 | Allogeneic CD19 and CD70-targeted CAR T therapy for autoimmune disease | In development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $22,000 |
| Research and development | $150.2 million | $192.3 million |
| Net income (loss) | -$190.9 million | -$257.6 million |
| Cash from operations | -$149.2 million | -$200.3 million |
| Cash and equivalents | $51.7 million | $75.2 million |
| Short-term investments | $198.5 million | $217.3 million |
Our latest story on this, dated Jun 22, 2026: "Allogene holders approve 800,000,000 shares; files ATM supplement for up to $135.0 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 14, 2025: "Allogene discloses Factor Bioscience patent suit against licensor Cellectis; it is not a party". The story links the filing or release it is based on. Read the story.
Allogene Therapeutics, Inc. trades under the ticker ALLO on NASDAQ.
Allogene Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Allogene Therapeutics, Inc. is 1737287. Its filings are on SEC EDGAR.
345,490,881 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Allogene Therapeutics, Inc. under United States.
Our directory classifies Allogene Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Allogene Therapeutics, Inc. is US0197701065.
aibio.space lists Allogene Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell product candidates, meaning off-the-shelf CAR T therapies made from healthy donor cells, for cancer and autoimmune diseases. Its three core programs are cema-cel, ALLO-316 and ALLO-329.
cemacabtagene ansegedleucel (cema-cel, ALLO-501A): Allogeneic CD19-targeted CAR T therapy for first-line large B-cell lymphoma Stage: Pivotal Phase 2 (ALPHA3), enrolling.
ALLO-316: Allogeneic CD70-targeted CAR T therapy for renal cell carcinoma
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Allogene Therapeutics, Inc. reported a net loss of $190.9 million for the fiscal year ended Dec 31, 2025, and used $149.2 million of cash in operations, per its annual report to the SEC.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio